Confo Therapeutics Secures $60 Million in Series B Funding for Breakthrough GPCR Drug Targeting Technology

Confo Therapeutics, a pioneering force in drug discovery, has successfully secured $60 million in funding to advance its groundbreaking technology focused on G protein-coupled receptors (GPCRs). This unique platform stabilizes functional conformations of GPCRs, enabling the identification of previously elusive drug targets. With this significant investment, Confo aims to bolster its multi-indication pipeline of drug candidates. The potential impact of this funding is considerable, as it may significantly enhance therapeutic outcomes for patients suffering from serious illnesses that currently lack effective disease-modifying treatments. Established in 2015 as a spin-off from Vrije Universiteit Brussel (VUB) and VIB, Confo Therapeutics draws on a wealth of scientific expertise and innovation from Belgium's rich life sciences ecosystem. The funding round has attracted a diverse array of international investors focused on life sciences, affirming confidence in the company’s vision and mission. With a distinguished team comprising seasoned entrepreneurs and prominent scientists from successful biopharmaceutical firms, Confo Therapeutics is poised to make significant strides in its research and development efforts. This latest round of funding will facilitate the acceleration of lead candidates into clinical trials, ultimately aiming to bring transformative therapies to patients in dire need. For more information about Confo Therapeutics and their innovative approach to drug discovery, visit www.confotherapeutics.com.